Revision surgery versus biologic treatment with omalizumab in recurrent chronic rhinosinusitis with nasal polyps: An analysis of cost-utility and clinical outcomes
Background: Both revision surgery and omalizumab are recommended therapies for the treatment of recurrent chronic rhinosinusitis with nasal polyps (CRSwNP) and can improve patients' clinical symptoms and quality of life (QoL). The aim of this study was to compare the improvement in sinus-relate...
Main Authors: | Yutong Sima, MS, Jing Zhang, MS, Ming Zheng, MD, Yan Zhao, PhD, Xiangdong Wang, MD, PhD, Luo Zhang, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | World Allergy Organization Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455123001060 |
Similar Items
-
Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers
by: Yutong Sima, MD, et al.
Published: (2025-01-01) -
Clinical effectiveness and potential predictability of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on the noninvasive markers – A real-life prospective study
by: Ming Zheng, MD, PhD, et al.
Published: (2022-10-01) -
Real-Life Effectiveness of Mepolizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps
by: María Sandra Domínguez-Sosa, et al.
Published: (2023-02-01) -
Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR
by: Laidlaw TM, et al.
Published: (2023-09-01) -
Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR [Corrigendum]
by: Laidlaw TM, et al.
Published: (2023-09-01)